Granulocyte-Macrophage Colony Stimulating Factor in Autologous Bone Marrow Transplantation: Augmentation of Graft versus Tumor Effect via Antibody Dependant Cellular Cytotoxicity

References

• Antman K. S., Griffin J. D., Elias E., Socinski M. A., Ryan L., Cannistra S. A., Oette D., Whitley M., Frei E. I., Schnipper L. E. Effect of recombinant granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med. 1988; 319: 593–598
   PubMed Web of Science ®Google Scholar
• Brandt S. J., Peters W. P., Atwater S. K., Kurtzberg J., Borowitz M. J., Jones R. B., Shpall E. J., Bast C. R., Glibert C. J., Oette D. H. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hemato-poietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 1988; 318: 869–876
   PubMed Web of Science ®Google Scholar
• Neumunaitis J., Singer J. W., Buckner C. D., Hill R., Rainer S., Thomas E. D., Appelbaum F. R. Use of recombinant human granulocyte/macrophage colony stimulating factor (rh GM-CSF) following autologous bone marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–836
   PubMed Web of Science ®Google Scholar
• Metcalf D. The granulocyte-macrophage colony stimulating factor. Science 1985; 229: 16–22
   PubMed Web of Science ®Google Scholar
• Golde D. W. Overview of myeloid growth factors. Semin. Hematol. 1990; 27: 1–7
   PubMed Web of Science ®Google Scholar
• Cannistra S. A., Griffin J. D. Regulation of the production and function of granulocytes and monocytes. Semin. Hematol. 1988; 25: 173–188
   PubMed Web of Science ®Google Scholar
• Kushner B. H., Cheung N. K. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989; 73: 1936–1941
   PubMed Web of Science ®Google Scholar
• Ho A. D., Haas R., Wulf G., Knauf W., Ehrhardt R., Heilig B., Körbling M., Schultz G., Hunstein W. Activation of lymphocytes induced by recombinant human granuloctye-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 1990; 75: 203–212
   PubMed Web of Science ®Google Scholar
• Wing E. J., Magee D. M., Whiteside T. L., Kaplan S. S., Shadduck R. K. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor recrosis factor α and interferon in cancer patients. Blood 1989; 73: 643–646
   PubMed Web of Science ®Google Scholar
• Ewnetos A. A., Snook D., Durbin H., Johnson P. M., Tgylor-Papadimitriou J. Limitations of radiolabelled monoclonal antibodies for localization of human neoplasms. Cancer Res. 1986; 46: 3183–3191
   PubMed Web of Science ®Google Scholar
• Kalofonos H., Rowlinson G., Epenetos A. A. Enhancement of monoclonal antibody uptake in human colon xenografts following irradiation. Cancer Res 1990; 50: 159–163
   PubMed Web of Science ®Google Scholar
• Charak B. S., Brynes R. K., Groshen S., Chen S. -C., Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990; 76: 2187–2190
   PubMed Web of Science ®Google Scholar
• Charak B. S., Choudhary G. D., Tefft M., Mazumder A. Interleukin-2 in bone marrow transplantation: pre-clinical studies. Bone Marrow Transplant 1992, (in press).
   Web of Science ®Google Scholar
• Charak B. S., Agah R., Mazumder A. Synergism of interleukin-2 and cyclosporine A in induction of a graft versus tumor effect without graft versus host disease after syngeneic bone marrow transplantation. Blood 1992; 80: 1–6
   PubMedGoogle Scholar
• Charak B. S., Brynes R. K., Katsuda S., Groshen S., Chen S. -C., Mazumder A. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin-2 therapy. Cancer Res 1991; 51: 2015–2020
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Ortaldo J. R., Mantonami A., Hobbs D. S., Kung H. -F., Pestka S. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell. Immunol. 1982; 67: 160–167
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Gottlieb D. J., Bianchi A. C. M., Meager A., Prentice H. G., Mehta A. B., Hofirand A. V., Brenner M. K. In vivo induction of γ interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous bone marrow transplantation. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Agah R., Malloy B., Kerner M., Mazumder A. Generation and characterization of IL-2-activated bone marrow cells as a potent graft VS tumor effector in transplantation. J. Immunol. 1989; 143: 3093–3099
   PubMed Web of Science ®Google Scholar
• Agah R., Malloy B., Kerner M., Girgis E., Bean P., Twomey P., Mazumder A. Potent graft antitumor effect in natural killer resistant disseminated tumors by transplantation of interleukin-2 activated syngeneic bone marrow in mice. Cancer Res 1989; 49: 5959–5963
   PubMed Web of Science ®Google Scholar
• Ujie T. Increased sensitivity of tumor cells to immune defense cells following treatment with antineoplastic agents in vitro. Jpn. J. Exp. Med. 1989; 59: 17–26
   PubMedGoogle Scholar
• Greenberg P. D. Interleukin-2 (IL-2) administered in vivo: influence of IL-2 route and timing on T-cell growth. J. Immunol. 1985; 134: 3895–3900
   PubMed Web of Science ®Google Scholar
• Gill I., Agah R., Hu E., Mazumder A. Synergistic antitumor effects of interleukin-2 and the monoclonal antibody Lym-l against human Burkitt's lymphoma cells in vitro and in vivo. Cancer Res. 1989; 49: 5377–5379
   PubMed Web of Science ®Google Scholar